EN DE
Watch Scancell Hldgs Plc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Scancell Hldgs Plc (SCLP) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Scancell Hldgs Plc stock £0.53, price £0.80, that is 33.4% below the price, quality 45 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare GB · ISIN GB00B63D3314

SH Scancell Hldgs Plc logo Thin data Nov 10, 2026

Scancell Hldgs Plc

SCLP · LSE
Expensive, weak quality

Our calculation puts a fair price 33% below what the stock costs today.

Quality 45/100
Negative equity (buybacks among others)
Mixed vs. peers (3/6)
Fair value £0.5329 · Overvalued
Weak Growth
Negative free cash flow
Narrow moat 23/100
Thin data
Estimate
Watch Scancell Hldgs Plc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

£2.70 £0.7500 Fair Value £0.5329 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range £0.7500 – £2.70 · fair‑value band £0.3997 – £0.6661 · the £0.8000 price screens above the £0.5329 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow Scancell Hldgs in your weekly email

Every Wednesday you see whether Scancell Hldgs is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Scancell Holdings plc, a clinical stage biopharmaceutical company, discovers and develops of immunotherapies for the treatment of cancer in the United Kingdom.

Show moreShow less

Its product candidates include SCIB1/iSCIB1+ that is in Phase II for the treatment of melanoma; and SC134, an antibody for the treatment of small cell lung cancer.

It also develops Modi-1, an active peptide immunotherapy that is in phase II clinical trials for the treatment of solid tumors, including renal, head and neck, ovarian and triple negative breast cancers; and Modi-2, which targets stress-induced post translational modifications, such as homocittrullination.

In addition, the company provides GlyMab platform that generates various affinity tumour specific monoclonal antibodies (mAb) targeting glycans that are over-expressed on cancer cells; and AvidiMab, which romotes receptor clustering thereby improving immune signalling.

Scancell Holdings plc was founded in 1996 and is based in Oxford, the United Kingdom.

Stock analysis

Scancell Hldgs Plc (SCLP) currently trades at £0.8000, while our estimate is £0.5329, 33% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: £0.3997 (bear) to £0.6661 (bull), the price of £0.8000 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 45/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is weak, negative or inconsistent.

Scancell Hldgs Plc reported revenue of £4.7M in FY2025 versus £0 in FY2021. Reported net income was −£17.9M in FY2026.

Key figures

Market cap £108M Micro · P/S ratio 26.0 · EPS (TTM) £−0.1700 · Return on equity −270% · Return on assets (EBIT) −75.8% (5-year average) · Revenue (TTM) £4.7M · Free cash flow −£10.6M · Net debt £11.8M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 23 out of 100 (medium confidence).

What moves the price

The share trades about 70% below its 52-week high and at its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −33%, SCLP screens richer than that median.

Fair Value

Bear £0.3997 Fair Value £0.5329 Bull £0.6661
Price £0.8000 · Downside -33.4%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 45/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 7
How much profit the company makes from its sales and capital
Quality Growth 50
Are margins and returns getting better?
Cashflow 27
Do the profits arrive as real cash?
Financial strength 33
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 43
How calm the share price moves, does not count
Price momentum 19
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 6
Distance to the 52-week high, does not count
New shares 100
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue growth is weak, negative or inconsistent.
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
43.9% (2007) → −318.4% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
not computed

SCLP screens overvalued: fair value 33% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Scancell Hldgs Plc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 849 stocks

Beats the industry median on 3/6 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 45 · Above median
Fair Value upside −33.4% · Below median
Profitability
Return on equity (12 months) Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Return on assets −172.8% · Bottom 25%
Operating margin (12 months) 0.0% · Above median
Growth and dividend
Revenue growth (quarter YoY) 0.0% · Above median
Balance sheet
Debt / equity Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
P/S (12 months) 22.84× · Priciest 25%

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $916.06 $1,275 +39% vs SCLP
Samsung Biologics Co 207940 1,468,000 KRW 1,661,000 KRW +13% vs SCLP
Vertex Pharmaceuticals Incorporated VRTX $547.89 $601.80 +10% vs SCLP
Genmab A/S GMAB kr 3,581 kr 3,880 +8% vs SCLP
argenx SE ARGX $971.55 $908.40 −7% vs SCLP
CSL Limited CSL A$201.68 A$181.40 −10% vs SCLP
Moderna, Inc MRNA $250.83 $158.70 −37% vs SCLP
BeOne Medicines AG 6160 HK$252.20 HK$152.80 −39% vs SCLP
Celltrion, Inc 068270 203,000 KRW 74,945 KRW −63% vs SCLP
Royalty Pharma plc RPRX $69.45 $19.01 −73% vs SCLP

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Scancell Hldgs Plc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Scancell Hldgs Plc Fair Value". https://www.fairvalue-calculator.com/stock/SCLP

Frequently asked questions

Is Scancell Hldgs Plc (SCLP) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is £0.5329 versus a price of £0.8000, about 33% lower (overvalued).
What is the fair value of SCLP?
Our estimate for Scancell Hldgs Plc is £0.5329 (as of Nov 10, 2026), built from audited fundamentals. The current price: £0.8000.
What is the quality score of SCLP?
Scancell Hldgs Plc has a Quality Score of 45/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Scancell Hldgs Plc (SCLP)?
Our calculated price target is the estimate of £0.5329 (as of Nov 10, 2026). Cautious scenario £0.3997, optimistic scenario £0.6661. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Scancell Hldgs Plc stock forecast for 2026?
Our estimate puts fair value at £0.5329, about 33% lower versus a price of £0.8000 (overvalued). Cautious scenario £0.3997, optimistic scenario £0.6661. The calculation is refreshed regularly with new filings.
What is the revenue of Scancell Hldgs Plc (SCLP)?
Scancell Hldgs Plc reported trailing-twelve-month revenue of about £4.7M (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Scancell Hldgs Plc (SCLP)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Scancell Hldgs Plc it is £0.5329 per share (as of Nov 10, 2026), against a price of £0.8000.
Is Scancell Hldgs Plc stock overvalued or undervalued in 2026?
As of Nov 10, 2026, SCLP trades above its calculated fair value: price £0.8000, fair value £0.5329, a gap of about −33% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of SCLP?
No. The price is what the market pays today (£0.8000); the fair value is what the company's own numbers justify (£0.5329). For Scancell Hldgs Plc the two are £0.2671 per share apart. That gap is exactly why we show both numbers side by side.
How much is Scancell Hldgs Plc worth?
The market values Scancell Hldgs Plc at about £108M (market capitalisation, as of Nov 10, 2026). Per share that is £0.8000; our models calculate a fair value of £0.5329 per share.
What do the bullish and bearish scenarios say about SCLP?
Our models span a range for Scancell Hldgs Plc: cautious scenario £0.3997, base £0.5329, optimistic £0.6661 per share (as of Nov 10, 2026, price £0.8000). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Scancell Hldgs Plc (SCLP)?
Balance-sheet figures for Scancell Hldgs Plc (as of Nov 10, 2026): negative equity, so no return on equity and no debt-to-equity ratio. They feed the Quality Score of 45/100, which measures business quality independently of the share price.
How far is SCLP from its 52-week high?
Scancell Hldgs Plc trades at £0.8000, about 70% below its 52-week high of £2.65 and at the low of £0.8000 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of £0.5329 is for.
Which stocks are comparable to Scancell Hldgs Plc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Scancell Hldgs Plc stock attractive at the current price?
The data as of Nov 10, 2026: price £0.8000, calculated fair value £0.5329 (−33%), Quality Score 45/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Scancell Hldgs Plc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Scancell Hldgs Plc (SCLP)?
The closing price on Nov 10, 2026 was £0.8000. Our estimate is £0.5329, about 33% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Scancell Hldgs Plc right now?
The price sits above even our optimistic bull case (£0.6661). The favourable scenario is already priced in. Weak quality (45/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Scancell Hldgs Plc

How large is the market capitalisation of Scancell Hldgs Plc (SCLP)?
The market capitalisation of Scancell Hldgs Plc is £108M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Scancell Hldgs Plc (SCLP)?
The price-to-sales ratio of Scancell Hldgs Plc is 26.0 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Scancell Hldgs Plc (SCLP)?
Earnings per share at Scancell Hldgs Plc are £−0.1700. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Scancell Hldgs Plc (SCLP)?
The return on equity (ROE) of Scancell Hldgs Plc is −270% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Scancell Hldgs Plc (SCLP)?
On an EBIT basis the return on assets of Scancell Hldgs Plc is −75.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does Scancell Hldgs Plc (SCLP) generate?
The free cash flow of Scancell Hldgs Plc is −£10.6M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Scancell Hldgs Plc (SCLP) carry?
The net debt of Scancell Hldgs Plc is £11.8M (fiscal year 2026). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Scancell Hldgs Plc in the live analysis

One click puts Scancell Hldgs Plc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.